Up a level |
Duell, Johannes, Maddocks, Kami J, Gonzalez-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, de Vos, Sven, Nagy, Zsolt, Obr, Ales, Gaidano, Gianluca, Abrisqueta, Pau et al (show 11 more authors)
(2021)
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
, Italy.
Duell, Johannes, Abrisqueta, Pau, Andre, Marc, Gaidano, Gianluca, Gonzales-Barca, Eva, Jurczak, Wojciech, Kalakonda, Nagesh ORCID: 0000-0002-5300-1360, Liberati, Anna Marina, Maddocks, Kami J, Menne, Tobias et al (show 7 more authors)
(2024)
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Haematologica, 109 (2).
pp. 553-566.